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Background. Plasminogen activator inhibitor-1 (PAI-1), the main inhib-
itor of plasminogen activators in plasma and in peritoneum, impairs
plasmin formation that is essential for the repair processes of the
mesothelium damaged by peritoneal dialysis fluids and peritonitis. The
fibrogenetic cytokine transforming growth factor-b (TGF-b) displays
variable effects on extracellular matrix remodeling enzymes and their
inhibitors depending on tissues and cell lines. We previously found an
unexpected stimulating effect of TGF-b1 on matrix metalloproteinase-9 in
peritoneal mesothelial cells. In this study, we analyzed the effects of
TGF-b1 on PAI-1 production and deposition in extracellular matrix.
Methods. We used primary cultured mesothelial cells and a recently
established human peritoneal mesothelial cell line (HMrSV5). Cell-
associated and secreted plasminogen activators and their inhibitors were
detected and characterized by substrate gel zymography. PAI-1 was
identified by reverse zymography and by Western blotting, and total PAI-1
was measured by ELISA. Secreted and cell-associated PA activity was
measured by its ability to activate plasminogen into plasmin, that is, by the
release of paranitroaniline from the plasmin synthetic substrate S-2251.
PAI-1 mRNA accumulation was assessed by Northern blot. In vitro
nuclear run-on assays were carried out to determine whether TGF-b1 had
transcriptional effects on PAI-1 expression. Finally, the subcellular distri-
bution of PAI-1 was analyzed by immunofluorescence and by immunogold
silver staining.
Results. TGF-b1 increased PAI-1 antigen in the conditioned media of
HMrSV5 cells, in a time- and concentration-dependent manner. This
induced a dramatic decrease of free tPA in the cell medium and of
membrane-bound uPA, and a parallel increase of high molecular weight
PA-PAI complexes. Consequently, secreted and cell-associated plasmino-
gen activator activities were considerably reduced. In primary cultured
peritoneal mesothelial cells, TGF-b1 also induced PAI-1 secretion and the
shift of tPA toward high molecular weight complexes. TGF-b1 increased
PAI-1 mRNA in a time- and concentration-dependent manner. This effect
was at least in part transcriptional since an ;threefold increase in the rate
of PAI-1 gene transcription was observed in nuclei sampled after a
four-hour cell exposure to 5 ng/ml TGF-b1. Finally, TGF-b1 substantially
increased the amount of intracellular and matrix-associated PAI-1.
Conclusions. These results suggest that excessive TGF-b1-stimulated
PAI-1 could prevent appropriate peritoneal healing by impairing the
degradation of fibrin and of unorganized matrix components, and by
interfering with cell migration.
The long-term use of peritoneal dialysis for the treat-
ment of patients with end-stage renal failure is compro-
mised by progressive ultrafiltration failure, which is com-
monly associated with a thickening of the peritoneal
basement membrane and with submesothelial peritoneal
fibrosis [1]. This complication results from the use of
hyperosmotic and acidic peritoneal dialysis fluids and from
the occurrence of peritonitis episodes that repeatedly dam-
age the mesothelium. Healing of the altered peritoneum
requires the degradation of fibrin and unorganized extra-
cellular matrix components that accumulate on the de-
nuded mesothelium, the restoration of a continuous me-
sothelial cell layer along the peritoneal cavity, and the
synthesis of a new basement membrane.
Plasmin is essential for these repair processes by its
ability to regulate inflammation and cell migration, and
more specifically to degrade fibrin and newly deposited
extracellular matrix components on which fibroblasts pro-
liferate and secrete interstitial collagens [2, 3]. Therefore,
inadequate fibrinolysis may account for the peritoneal
fibrotic thickening that occurs after long-term peritoneal
dialysis. Plasmin activity is regulated by the plasminogen
activators (PA), urokinase PA (uPA) and tissue-type PA
(tPA), which convert the inactive zymogen plasminogen
into active plasmin, and by their inhibitors [4]. Plasminogen
activator inhibitor-1 (PAI-1) is the major inhibitor of
plasminogen activators in plasma and in peritoneum [5, 6].
It inhibits both tPA and uPA activities by forming enzy-
matically inactive equimolar PA-PAI complexes. PAI-1
may be regulated by different cytokines and growth factors
among which TGF-b plays a pivotal role. Indeed, TGF-b
stimulates PAI-1 secretion in various cell lines [7] and in
vivo [8].
A large body of evidence suggests that mesothelial cells
themselves could play a role in the repair process of the
mesothelium. First, they produce a variety of extracellular
matrix components including fibronectin, laminin and type
IV collagen [9, 10]. Second, they are directly involved in
the fibrinolytic pathways, since they exhibit a plasmino-
gen activator-dependent fibrinolytic activity due to the
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production of secreted free tPA and cell-bound uPA. This
fibrinolytic activity is reduced in inflammatory states [6, 11].
Third, mesothelial cells are stimulated by pro-inflammatory
cytokines to secrete anti-inflammatory cytokines [12] in-
cluding transforming growth factor-b (TGF-b) [13]. In
addition to its anti-inflammatory properties, TGF-b is also
the leader of fibrogenetic cytokines: it increases production
of extracellular matrix components, and it usually decreases
protease activities by reducing protease production and by
increasing protease inhibitor synthesis [3, 14].
The mechanisms whereby TGF-b that is released in the
peritoneal cavity upon mesothelial aggression induces ex-
tracellular matrix (ECM) accumulation in the peritoneal
wall are, however, more complex than anticipated, due to
the variable effects of this cytokine on ECM remodeling
enzymes and their inhibitors, depending on tissues and cell
lines [8, 15–17]. In a previous study [18] we indeed found an
unexpected stimulating effect of TGF-b1 on matrix metal-
loproteinase-9 (MMP9) in cultured human peritoneal me-
sothelial cells. Since MMP9 degrades type IV and dena-
tured collagens, we hypothesized that TGF-b could favor
mesothelial healing by facilitating removal of denatured
collagens, but that an excessive TGF-b activity might be
fibrogenetic by enhancing the replacement of basement
membrane type IV collagen by TGF-b induced interstitial
collagens.
TGF-b also stimulates PAI-1 [7, 8], which both inhibits
plasmin formation hence activation of pro-MMPs [3], and
interferes with cell migration [19–22]. However, in vivo
studies have shown that the PAI-1 gene is regulated in a
complex and tissue-specific manner, and, therefore, its
activation may be different from a cell lineage to another
[8]. The aim of this work was to analyze the effects of
TGF-b1 on PAI-1 production and deposition in ECM, by
using well-characterized primary cultured mesothelial cells
and a recently established human mesothelial peritoneal
cell line [18]. Our results indicate that in mesothelial cells,
TGF-b1 is not only a potent stimulator of PAI-1 production
as a result of a transcriptional effect, but it also dramatically
increases PAI-1 deposition in ECM, which may affect
re-mesothelialization of the denuded peritoneum.
METHODS
Cultures of peritoneal mesothelial cells
Isolation of peritoneal mesothelial cells and primary
cultures were performed as already reported [18, 23]. The
SV40 immortalized peritoneal mesothelial cell line
(HMrSV5) has been previously described [18]. It was
established after infection of a fully characterized primary
culture of human peritoneal mesothelial cells with an
amphotropic recombinant retrovirus that encodes SV40
large-T Ag under the control of the Moloney virus long
terminal repeat (LTR) and resistance to the antibiotic
G418.
Both primary cultured and immortalized cells were
grown in type I collagen-coated dishes in Dulbecco’s mod-
ified Eagle medium (DMEM) containing 10% heat-inacti-
vated fetal calf serum (FCS; complete medium). All exper-
iments on immortalized mesothelial cells were performed
between passages 5 and 10.
Experimental protocols
Confluent primary cultured or immortalized peritoneal
mesothelial cells were incubated in serum-free medium for
24 hours before testing the effects of TGF-b1.
To assess the effect of TGF-b1, confluent and non-
confluent cultures were incubated for 0.5 to 24 hours in
serum-free medium supplemented or not with 0.1 to 10
ng/ml TGF-b1. Harvested media were immediately centri-
fuged at 700 g for five minutes at 4°C to discard non-
adherent cells and then stored at 240°C until use. After
two washes in serum-free medium, cells were lysed in
sample buffer [62.5 mM Tris (pH 6.8), 10% glycerol, 4%
SDS, 0.005% Brilliant blue R] for cell extract studies or in
0.1 M NaOH for protein quantitation. Cell viability was
assessed by trypan blue exclusion and was more than 95%
in all experiments. The effects of experimental conditions
were assessed in at least three independent experiments.
Fibrin gel zymography and reverse zymography
Cell-associated and secreted plasminogen activators
were detected and characterized by substrate gel zymogra-
phy [24] as already described [25]. Human uPA and tPA
were run in parallel as standards. In some experiments,
polyclonal anti-uPA or anti-tPA neutralizing antibodies
were added to the agarose fibrin gel. Reverse fibrin zymog-
raphy was performed by adding 4 IU/ml uPA to the fibrin
gel. Photographs of the fibrin plates were taken with
indirect illumination on a black background. All zymo-
grams presented in the Figures are representative of at
least three independent experiments performed in tripli-
cate cultures. Samples were normalized to cellular protein
content. The volume of conditioned medium loaded in
each lane corresponded to 1 to 5 mg of cellular protein.
Same results were obtained when samples were normalized
to cell number.
PAI-1 level and plasminogen activator activity
determinations
Total PAI-1 was measured by commercially available
enzyme immunoassay that detected active and inactive
forms of PAI-1 as well as PAI-1 complexed to PA (TintEl-
ize PAI-1; Biopool, Umeå, Sweden). Sensitivity of the assay
was 0.5 ng/ml.
Plasminogen activator activity of conditioned media or of
cell layers from duplicate cultures was measured by its
ability to activate plasminogen into plasmin; plasmin activ-
ity was determined by the release of paranitroaniline from
the plasmin synthetic substrate S-2251 [26]. A total of 150
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ml S-2251 (3 mM in phosphate buffer saline, pH 7.4) and
plasminogen (25 mCU/ml) were added to 150 ml condi-
tioned media and incubated at 37°C for eight hours. The
washed cell layer was incubated with 500 ml S-2251 (1 mM
in phosphate buffer saline, pH 7.4) and plasminogen (25
mCU/ml) at 37°C for eight hours, after which the reagent
medium was harvested and centrifuged to discard cells and
debris. Aliquots (100 ml) were distributed in duplicate in
96-well flat bottom microtiter plates. The release of para-
nitroaniline from S-2251 was determined by measuring the
absorbance at 405 nm with an ELISA plate reader. Results
were expressed in absorbance units.
Western blot analysis
Conditioned media were separately concentrated by
centrifugation using Amicon columns with a 10 kD cut-off.
Samples of concentrated media normalized to cellular
protein content or to cell number were analyzed by West-
ern blot as already described [18]. The presence of PAI-1
and PA was detected respectively with a mouse monoclonal
anti-human PAI-1 antibody (1 mg/ml), and with a goat
polyclonal anti-human tPA (2 mg/ml) or anti-human uPA
(4 mg/ml) antibody. Negative controls used an irrelevant
mouse monoclonal antibody (MOPC21) or normal goat Ig.
mRNA isolation and Northern blot
For each experimental condition, approximately 107
HMrSV5 cells grown in 100-mm diameter Petri dishes were
lysed in 4 M guanidium thiocyanate, 25 mM sodium acetate
(pH 7), 0.5% sodium N-lauroylsarcosine (wt/vol), 100 mM
b-mercapto-ethanol, according to Chomczynski and Sacchi
[27].
To analyze the effects of protein or mRNA synthesis
inhibition, some experiments were performed by incubating
the cells with 5 mg/ml cycloheximide (Cxd) for one or four
hours prior to and during TGF-b1 stimulation, before
mRNA isolation.
Total RNAs were then extracted with the Qiagen
RNeasy total mRNA kit. The RNA concentration in each
sample was determined by spectrophotometry and only
samples with 260/280 ratio close to 1.9 were analyzed.
RNAs (15 mg per lane) were then studied by electrophore-
sis in 1.2% formaldehyde-agarose gels and transferred to
Nylon Hybond N membrane in 2 3 SSC. Membranes were
prehybridized for three hours at 42°C (GAPDH) or 65°C
(PAI-1) in 50% formamide (vol/vol), 25 mM sodium phos-
phate (pH 6.3), 13 prehybridization solution. They were
then hybridized for 18 hours at 42°C (GAPDH) or 65°C
(PAI-1 probe) in 50% formamide (vol/vol), 5% dextran
sulfate (wt/vol), 20 mM sodium phosphate (pH 6.3), 13
hybridization solution, with cDNA probes labeled with
[a-32P]dCTP to approximately 3 to 5 108 cpm/mg of DNA
by the random priming method. Afterwards, membranes
were washed for 10 minutes at 42°C in three successive
buffers: 2 3 SSC, 0.1% SDS; 1 3 SSC, 0.1% SDS; 0.1 3
SSC, 0.1% SDS. Quantification was performed by exposing
the filters to X-ray Fuji films (Fuji, Tokyo, Japan) with
intensifying screen for 48 to 72 hours at 270°C followed by
densitometric scanning of the bands.
HMrSV5 nuclei isolation and in vitro nuclear run-on
assay
Nuclear run-on experiments were carried out as de-
scribed by Greenberg and Ziff [28] with minor modifica-
tions as already reported [29]. Probes were linearized
PAI-1 or GAPDH cDNA containing plasmid or plasmid
alone. Quantification of specific [a-32P]-labeled mRNA
hybridization was performed by exposing the filters to
X-ray Fuji films with intensifying screen for 48 to 72 hours
at 270°C, followed by densitometric scanning of the bands.
Immunocytochemistry
For cell characterization, immunofluorescence studies
were performed on mesothelial cell monolayers grown in
collagen coated Petri dishes as already described [18].
Morphological studies of TGF-b1-induced PAI-1 stimu-
lation were performed by immunofluorescence (IF) and by
immunogold silver staining technique (IGSS) essentially as
previously described [30]. Briefly, cells were grown to
subconfluence on collagen coated glass slides and stimu-
lated or not with TGF-b1 as described above in the
“Experimental Protocols” section before fixation with
0.25% glutaraldehyde. For IF studies, cells were washed,
permeabilized with 0.2% Triton X100, then pretreated with
sodium borohydrate (0.1% wt/vol) for 10 minutes to inhibit
glutaraldehyde-induced fluorescence [31]. After extensive
wash, the cells were incubated for 18 hours at 4°C with the
anti-PAI-1 monoclonal antibody, washed again and incu-
bated for two hours with a biotinylated anti-mouse IgG
antibody. The cells were then incubated with avidin conju-
gated to FITC for two hours, washed, and mounted in
Dako® fluorescent mounting medium for examination.
For IGSS, the slides were treated with the anti-PAI-1
monoclonal antibody as described for IF, washed, then
incubated with 1 mg/ml gold labeled F(ab9)2 goat anti-
mouse IgG for two hours at room temperature. Afterwards,
they were washed in distilled water before amplification
with the silver enhancement reagent and counterstaining
with Giemsa. The slides were examined with combined
brightfield and epipolarization microscopy with a Leitz
microscope.
Materials
Human transforming growth factor b1 (TGF-b1) was
purchased from Genzyme (Cambridge, MA, USA); avidin-
FITC, bovine thrombin from Sigma Chemicals (St. Louis,
MO, USA). Mouse monoclonal anti-PAI-1 antibody and
anti-tPA antibody from Biopool (Umeå) were used for
Western blot. The anti-WT1 mouse monoclonal antibody
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6FH2, was provided by F.J. Rauscher III, (The Wistar
Institute, Philadelphia, PA, USA). For IF and IGSS, the
mouse monoclonal anti-PAI-1 antibody was from
Monozyme, Aps, Denmark, the biotinylated anti-mouse
IgG antibody from Vector Laboratories (Burlington, CA,
USA), the gold labeled F(ab9)2 goat anti-mouse IgG from
Aurion (Wageningen, The Netherlands) and the silver
enhancement reagent from Biocell (Cardiff, Wales, UK).
Human fibrinogen was obtained from CTS Lille (Lille,
France), human plasminogen from Chromogenix (Mo¨ln-
dal, Sweden), and human purified urokinase from Hoechst
(Puteaux, France). The RNeasy total mRNA kit was from
Qiagen (Chatsworth, CA, USA). [a-32P]dUTP was pro-
vided by ICN (Costa Mesa, CA, USA). Prehybridization
and hybridization solutions were purchased from Gibco
BRL (Gaithersburg, MD, USA). Cell protein content was
assessed using a BCA protein assay® (Pierce, Rockford, IL,
USA). Random priming DNA labeling kit was from MBI
Fermentas (Vilnius, Lithuania). [a-32P]dCTP, Hybond N
filters and nitrocellulose membranes were from Amersham
Corp. (Arlington Heights, IL, USA).
The PAI-1 cDNA was kindly provided by E.K.O.
Kruithof (Hoˆpital Cantonal Universitaire de Gene`ve, Ge-
ne`ve, Switzerland) and have been described in [32]. The
PAI-1 probe was an EcoRI 2.9 kb PAI-1 cDNA subcloned
into pBluescript vector. The glyceraldehyde-3-phosphate
deshydrogenase (GAPDH) probe was obtained by subclon-
ing a 780 bp XbaI/PstI fragment of the GAPDH cDNA (1.2
kb, N° 57090; ATCC, Rockville, MD, USA) into a pBlue-
script vector and was used to normalize the relative expres-
sion of mRNA. All the other materials used have already
been described [18].
Statistics
All results including semiquantitative densitometric anal-
ysis were expressed as means 6 SEM of three experiments.
Differences between means were evaluated with Student’s
t-test. P , 0.05 was considered statistically significant.
RESULTS
Characterization of human peritoneal mesothelial cells
Primary cultured mesothelial cells and HMrSV5 cells
were characterized exactly as previously described [18].
Both cell populations exhibited the same morphology and
phenotypic markers during the exponential phase of growth
and at confluence. They co-expressed cytokeratin 18 and
vimentin, a characteristic feature of mesothelial cells. They
produced interstitial collagens (types I and III) and base-
ment membrane collagen (type IV), as well as PAI-1/
mesosecrin. In addition, they expressed the specific nuclear
transcription factor WT1, as shown by Western blot anal-
ysis of nuclear extracts (not shown) and by immunofluores-
cence. In contrast, they failed to express the endothelial
markers CD31 and vWF (Table 1).
Characterization of PAs and PAI produced by HMrSV5
Fibrin gel zymograms of conditioned media revealed two
major lytic zones at 110 kD and 60 kD (Fig. 1A). Co-
polymerization of the fibrin gel with polyclonal anti-tPA
neutralizing antibodies inhibited the 110 kD- and 60 kD-
lytic bands (Fig. 1B), thus indicating the presence of
complexed and free tPA, respectively. Western blot analysis
of whole concentrated conditioned media with specific
polyclonal anti-tPA antibodies revealed two bands with
apparent molecular weights of 110 kD and 60 kD (Fig. 1G).
uPA Ag was not detected in concentrated media (not
shown).
Fibrin gel zymograms of cellular extracts showed mainly
a 55 kD band together with weak bands at 60 kD and 110
kD (Fig. 1C). Co-polymerization of the fibrin gel with
polyclonal anti-tPA neutralizing antibodies inhibited the
110 kD- and 60 kD-lytic bands (Fig. 1D), whereas the 55 kD
band only was abolished by addition of polyclonal anti-uPA
neutralizing antibodies (Fig. 1E), suggesting the presence
of cell-bound uPA unassociated with PAI-1.
PAI-1 was detected at the expected apparent molecular
weight of 48 to 50 kD by reverse zymography (Fig. 1F) and
by Western blotting (Fig. 1H) of concentrated conditioned
media. PAI-2 was not detected.
Modulation of PAs and PAI-1 by TGF-b1 in HMrSV5
cell cultures
Because TGF-b is secreted by mesothelial cells [13;
Rougier et al, unpublished observations] and is most likely
released in the peritoneal cavity during peritonitis, we
studied the effects of TGF-b1 on PAs and PAI-1.
TGF-b1 decreased free tPA and non-complexed uPA,
respectively, in conditioned media (Fig. 2A) and in cell
extracts (Fig. 2B) from cell cultures incubated for 24 hours
with this cytokine. The dramatic decrease of PAs was
associated with a substantial increase of higher molecular
weight complexes (molecular weight around 110 kD; Fig.
2A and 2B). The latter were most likely composed of the
respective PA associated with PAI-1, since the lytic area
disappeared only in the presence of the relevant anti-tPA
or anti-uPA antibody (not shown). The effect of TGF-b1
Table 1. Characteristics of primary cultured mesothelial cells and
HMrSV5 cell line studied by immunofluorescence
Primary cultures HMrSV5 cells
Cytokeratin 18 1 1
Vimentin 1 1
Type I collagen 1 1
Type III collagen 1 1
Type IV collagen 1 1
PAI-1/mesosecrin 1 1
von Willebrand factor 2 2
CD31 2 2
WT1 1 1
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peaked around 5 ng/ml for tPA (Fig. 2A) and continued to
increase up to 10 ng/ml for uPA (Fig. 2B).
The effect of TGF-b1 on PAs was associated with a
concentration-dependent increase in total PAI-1 antigen as
assessed by immunoenzymatic assay (Fig. 2C).
Because PAI-1 could be in an inactive form [7], we tested
the effect of a 24-hour exposure to 5 ng/ml TGF-b1 on total
PA activity of conditioned media and of cell layers mea-
sured with the plasmin chromogenic substrate S2251 in the
presence of plasminogen (Fig. 2D). We observed a dra-
matic decrease in soluble (conditioned media) and cell
bound (cell layers) PA activity in cultures incubated with
Fig. 1. Fibrin gel zymography and immunoblot analysis of plasminogen activators (PA) and their inhibitors (PAI) produced by HMrSV5 cells.
Aliquots (20 ml) of 24-hour serum-free conditioned media (A, B, F, G, H) or cell extract (C, D, E) from HMrSV5 confluent cultures were analyzed by
fibrin zymography (A-E), reverse fibrin zymography (F), or Western blot (G, H) as indicated in the Methods section. Plasminogen activator activity was
indicated as lytic zones of the substrate (A-E). Urokinase PA (uPA) and tissue-type PA (tPA) were identified according to their plasminogen-dependent
fibrinolytic activity (A, C), their molecular weight (A, C) compared to standards run in parallel (human tPA and uPA), and the inhibition of their PA
activity with specific neutralizing antibodies (B, D, polyclonal anti-tPA antibody; E, polyclonal anti-uPA antibody). Neutralizing antibodies to tPA
abolished the activity of both free and complexed forms (B, D). Note the constitutive expression of free and complexed tPA (A) and the large
predominance of non-complexed uPA in cellular extracts (C). Reverse zymography revealed a single PAI with the expected molecular weight of 48 to
50 kD (F). For Western blot analysis (G, H), concentrated (330 to 40) conditioned media were first submitted to electrophoresis under non reducing
(G) or reducing (H) conditions in 8% polyacrylamide gels, then transferred onto nitrocellulose. Antigen identification was performed with specific
polyclonal antibodies to tPA (G) or with a specific monoclonal antibody to PAI-1 (H). Anti-tPA antibody revealed two main bands with apparent
molecular weights of 60 kD and 110 kD corresponding to free tPA and to tPA-PAI complex, respectively (G). Anti-PAI-1 antibody recognized PAI-1
antigen at the expected molecular weight of 48 to 50 kD (H). Controls using isotype-matched irrelevant monoclonal or polyclonal antibodies were
negative (not shown).
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TGF-b1. These results are in keeping with the disappear-
ance of free PAs by zymography (Fig. 2 A, B) and the
increase of PAI-1 antigen (Fig. 2C).
The effect of TGF-b1 was further analyzed as a function
of time. It was maximal from 12 hours but it could be
observed as early as four hours (Fig. 3A). The increase in
secreted PAI-1 was also demonstrated by reverse zymogra-
phy (Fig. 3B) and by Western blot (Fig. 3C) after an
18-hour stimulation with 5 ng/ml TGF-b1.
Modulation of PAI-1 by TGF-b1 in primary cultures of
peritoneal mesothelial cells
To further establish the relevance of the HMrSV5 model
for testing the effects of TGF-b1 on PAs in mesothelial
cells, primary cultures of peritoneal mesothelial cells from
five different patients were exposed to TGF-b1 using the
same experimental protocol as for HMrSV5 cells. Similar
zymograms of conditioned media (Fig. 4A) and of cell
extracts (not shown) were obtained, indicating the presence
of free tPA and of uncomplexed cell-associated uPA,
respectively. As observed for HMrSV5 cells, TGF-b1 (5
ng/ml) induced the disappearance of free tPA in condi-
tioned media (Fig. 4A), due to a dramatic increase of total
PAI-1 (Fig. 4B). This effect was also time- and concentra-
tion-dependent (not shown).
Therefore, HMrSV5 cells were used as a model of
peritoneal mesothelial cells in all further experiments
aimed at analyzing the mechanisms of TGF-b1-induced
stimulation of PAI-1 as well as PAI-1 subcellular distribu-
tion and deposition in ECM.
Transcriptional regulation of PAI-1 by TGF-b1 in
mesothelial cells
Treatment of HMrSV5 cells for eight hours with 0.1 to 10
ng/ml TGF-b1 increased PAI-1 mRNA levels in a concen-
tration-dependent manner with a maximum at 5 ng/ml (not
shown). This stimulation was also time-dependent (Fig. 5).
It appeared after only two hours of exposure to TGF-b1,
peaked at four to six hours, and then declined to the
prestimulatory level that was reached after 18 to 24 hours
(Fig. 5). Under control conditions, PAI-1 mRNA size was
3.5 kb. A 2.4 kb species was additionally observed after four
to six hours of stimulation with TGF-b1 and decreased
thereafter. In the same experiments, we did not detect any
effect of TGF-b1 on GAPDH mRNA content (Fig. 5).
Although cycloheximide (Cxd) alone has no effect on
PAI-1 gene transcription [33, 34], we tested its effects on
PAI-1 mRNA levels in both unstimulated and TGF-b1-
stimulated mesothelial cells. Incubation of the cells with
Cxd (5 mg/ml) for one or four hours prior to TGF-b1
stimulation completely abolished the accumulation of both
3.2 and 2.4 kb mRNA species (not shown) which suggested
that the increase in PAI-1 specific mRNA required protein
synthesis.
Fig. 2. Effects of transforming growth factor-
b1 (TGF-b1) on plasminogen activators and
plasminogen activator inhibitor-1 (PAI-1) in
HMrSV5 cell cultures. Confluent HMrSV5 cell
cultures were incubated for 24 hours with
serum-free medium supplemented or not with
TGF-b1. Samples of conditioned media (A) or
of cell extracts (B) normalized to cell protein
content were analyzed by fibrin zymography.
Arrows indicate the position of free tPA and
uPA, and of PAI-PA complexes. In the
presence of TGF-b1, free tPA activity (60 kD)
was shifted to a higher molecular weight PA
activity around 110 kD which corresponds to
PA-PAI-1 complexes (A). (C) The control
condition without TGF-b1. Note that the effect
of TGF-b1 was concentration-dependent.
Similarly, uPA activity in cellular extracts was
shifted to higher molecular weight uPA-PAI-1
complexes in a TGF-b1 concentration-
dependent manner (B). The effect of TGF-b1
on PAs was associated with a concentration-
dependent increase in total PAI-1 antigen as
assessed by immunoenzymatic assay (C). ,P ,
0.05. The total PA activity of conditioned media
and of cell layers previously exposed to 5 ng/ml
TGF-b1 for 24 hours was evaluated with the
plasmin chromogenic substrate S2251 as
described in the Methods section. Note that
TGF-b1 induced a major decrease of PA
activity (D). Symbols are: (f) TGF-b1 (5 ng/
ml); (M) control medium; , ,P value , 0.001.
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To determine whether TGF-b1 had transcriptional ef-
fects, we performed comparative run-on transcription as-
says with nuclei isolated from cells cultured for four hours
in the presence or in the absence of TGF-b1 (Fig. 6).
Labeled nascent RNA transcripts were hybridized to mem-
brane bound cDNA probes specific for PAI-1 and
GAPDH. The results of one typical experiment are shown
in Figure 6. Densitometric analysis indicated that TGF-b1
induced an ;threefold increase (mean 5 3.15, range 2.29
to 4.03) in the rate of PAI-1 gene transcription.
TGF-b increases intracellular and matrix associated
PAI-1 in HMrSV5 cells
Because secreted PAI-1 may be associated with extracel-
lular matrix and may thus regulate cell migration [19–22]
and membrane-associated protease activity, we studied
both intracellular and matrix-associated PAI-1 by IF and
IGSS, respectively (Fig. 7).
In unstimulated cell cultures, intracellular PAI-1 was
detected by IF in small intracytoplasmic mostly perinuclear
vesicles (Fig. 7A). Intracellular labeling intensity varied
from one cell to another. Extracellular PAI-1 was localized
by IGSS in the close pericellular environment of cells (Fig.
7C).
In cultures stimulated with 5 ng/ml TGF-b1, intracellular
PAI-1 was markedly increased after four hours (Fig. 7B).
All cells were then intensely stained with an increase in
both the number and the size of PAI-1 containing vesicles
(Fig. 7B). However, at this time point, matrix-associated
PAI-1 analyzed by IGSS was not yet modified when com-
pared to control (not shown). After 24 hours of incubation
with TGF-b1, a persistent increase in intracellular PAI-1
was observed by IF (not shown). Cells became more
elongated and spread over the extracellular matrix and the
neighboring cells. Simultaneously, in areas uncovered by
cells, extracellular PAI-1 was detected by IGSS on the
whole extracellular matrix surface with a continuous distri-
bution (Fig. 7D). The overall IGSS staining was much more
intense than in unstimulated cells.
DISCUSSION
PAI-1 was first described as “mesosecrin,” a glycoprotein
produced in abundance by mesothelial cells in vivo and in
vitro [35], until the cloning of mesosecrin cDNA revealed its
identity with PAI-1 [36]. This glycoprotein plays a pivotal
role in fibrinolytic and fibrogenetic processes by inhibiting
PAs, and consequently a cascade of events including con-
version of plasminogen into plasmin, plasmin-induced fi-
brin degradation and activation of the pro-enzymatic forms
of matrix metalloproteinases. In addition, recent data sug-
gest that PAI-1 is implicated in cell-matrix interactions that
involve the binding of membrane receptors, including
uPAr, and integrins to ECM components such as vitronec-
tin [19–21]. These interactions seem to regulate, in a subtle
manner, cell attachment and mobility depending on the
balance between uPA and PAI-1. Therefore, PAI-1 could
play an important role in peritoneum barrier pathophysi-
ology, particularly in re-mesothelialization and in perito-
neum fibrotic thickening that occur in patients on perito-
neal dialysis.
In this work using primary cultures and a derived SV40
immortalized cell line [18] of human peritoneal mesothelial
cells, we analyzed the effects of TGF-b1 on PAI-1 secre-
tion, and subcellular and matrix localization. We showed
that TGF-b1: (i) dramatically increased production of
active PAI-1 and consequently markedly reduced PA activ-
ity, (ii) increased PAI-1 expression in mesothelial cells both
intracellularly in secretory vesicles and extracellularly in the
pericellular environment, and (iii) exerted transcriptional
effects on PAI-1 gene. TGF-b1 not only increased the 3.2
kb PAI-1 mRNA transcript but also induced that of 2.4 kb,
Fig. 3. Time-dependent effects of TGF-b1 on PAI-1 secreted by HMrSV5
cells. HMrSV5 cell cultures were incubated for 0.5 to 24 hours with
serum-free medium supplemented (f) or not (control; M) with 5 ng/ml
TGF-b1. TGF-b1 induced a time-dependent increase in total PAI-1
antigen as assessed by immunoenzymatic assay (A). ,P , 0.05. Samples of
conditioned media normalized to cell protein content were also analyzed
after 18 hours of exposure to TGF-b1, by reverse fibrin zymography (B)
and, after concentration (330 to 340), by Western blot (C). Note the
substantial increase in PAI-1.
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which results from alternative cleavage and polyadenyla-
tion, and is only observed in human and higher primates
[32, 33, 36, 37]. Both mRNA species showed a parallel
time-dependent induction profile, contrasting with the de-
layed induction of the 2.4 kb form in hepatoma cells
HepG2 stimulated with PMA [34]. Although TGF-b1
clearly enhanced PAI-1 mRNA transcription as shown by
run-on analysis, we cannot rule out an additional stabilizing
effect of TGF-b1 on PAI-1 mRNAs as previously reported
in other cells [33] or for other extracellular proteins [38].
The dramatic increase of PAI-1 after TGF-b1 stimula-
tion of peritoneal mesothelial cells may hamper appropri-
ate peritoneal healing and favor fibrogenesis after chemical
or infectious aggressions by at least three mechanisms.
First, PAI-1 may prevent re-mesothelialization of the de-
nuded mesothelium by the remaining mesothelial cells or
by uncommitted cells migrating from the underlying con-
nective tissue [1]. PAI-1 exhibits high affinity not only for
PAs but also for ECM components including vitronectin
[39]. In our model, binding of PAI-1 to ECM components
is illustrated by IGSS data in TGF-b1-stimulated mesothe-
lial cells. Mesothelial cells express both the avb3 vitronectin
receptor (VNr) [40] and the uPAr [41], which both may be
involved in adhesion to vitronectin and in mesothelial cell
migration. It is not clear yet whether mesothelial cells use
uPAr to adhere to vitronectin, or if they adhere to vitro-
nectin via avb3. However, if the VNr (avb3) is required for
mesothelial cell migration, the excess of PAI-1 in TGF-b-
stimulated cells may inhibit cell migration by preventing
VNr-vitronectin interactions [19]. On the other hand, in the
setting of uPAr/vitronectin interactions, PAI-1 is able to
promote migration of cells probably by lowering the
strength of uPAr adhesion to vitronectin [20, 21]. This is
consistent with our observation of a trail of PAI-1 behind
migrating cells in unstimulated mesothelial cell cultures
(not shown). However, in TGF-b1-treated mesothelial cell
cultures, cells are forced to migrate on PAI-1-saturated
vitronectin to which uPAr is unable to bind. The migratory
potential of such cells unable to use their uPAr to adhere to
vitronectin may be considerably reduced. Finally, in addi-
tion to its direct influence on cell-matrix interactions, PAI-1
also inhibits plasmin formation and hence activation of
matrix metalloproteinases, a class of enzymes that stimulate
cell migration by enhancing matrix remodeling. Thus, the
substantial increase of PAI-1 induced by TGF-b1 most
likely hampers the migration of mesothelial cells, and
consequently the repair of the denuded mesothelium.
Second, PAI-1 may inhibit fibrin removal and thus favor
the deposition of a fibrin coat on which fibroblasts prolif-
erate and secrete interstitial collagens [2, 3]. Mesothelial
cells are endowed with high fibrinolytic activity due to the
secretion of tPA and of membrane-bound uPA [6, 41]. In
addition, plasminogen is present at high concentration in
the peritoneal cavity of patients on CAPD (J.-Ph. Rougier,
unpublished data). Inflammatory mediators, including LPS
[41] and the inflammatory cytokines interleukin (IL)-1 and
tumor necrosis factor-a (TNF-a) [6, 41, 42] released during
the acute phase of peritonitis in CAPD patients, inhibit
fibrinolytic activity, whereas the procoagulant activity as-
sessed by tissue factor mRNA expression is increased [41].
Our results suggest that the anti-inflammatory cytokine
TGF-b1, whose production is stimulated by the above
Fig. 4. Effects of TGF-b1 on plasminogen activators and PAI-1 in primary cultures of human mesothelial cells. (A) Fibrin zymography of conditioned
media sampled from cell cultures treated for 24 hours with 5 ng/ml TGF-b1 or left untreated (control). In the presence of 5 ng/ml TGF-b1, free tPA
activity (60 kD) was shifted to a higher molecular weight PA activity around 110 kD, which corresponds to PA-PAI-1 complexes. (B) Immunoenzymatic
assay showing that at the same concentration, TGF-b1 had a stimulating effect on PAI-1 antigen similar to that observed in HMrSV5 cell cultures
(compare with Fig. 3B). ,P , 0.005.
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inflammatory cytokines at the healing phase of peritonitis
[13], could be responsible for persistent anti-fibrinolytic
activity due to a dramatic increase of PAI-1 production.
Third, it is likely that PAI-1 is an important profibroge-
netic mediator acting mainly by inhibiting plasmin-induced
activation of matrix metalloproteinases [3]. The most con-
vincing evidence has been provided by the tight correlation
of PAI-1 levels with lung fibrosis in mice that were engi-
neered to either overexpress or be completely deficient in
PAI-1 [43, 44]. The profibrogenetic role of PAI-1 is also
indirectly supported by the important protective effects of
tPA-induced plasmin generation in experimental crescentic
glomerulonephritis [45]. Also, in humans the development
of glomerular [46] and lung [47, 48] fibrosis has been
correlated with increased PAI-1 secretion. It has been
shown that PAI-1 was overexpressed by fibroblasts in keloid
Fig. 6. Nuclear run-on transcription assay.
The same amount (5 mg) of plasmid DNA
containing the PAI-1 probe (upper), plasmid
alone (center) and plasmid DNA containing the
GAPDH probe (lower) was blotted on Hybond
N1 membranes, and hybridized with ;5 3 107
cpm of 32P-labeled nascent RNAs prepared
from cells cultured for four hours in the
absence (Control) or in the presence (TGF-b1)
of 5 ng/ml TGF-b1. Intensity of the
hybridization signal obtained with the PAI-1
cDNA probe was increased by threefold
whereas that of the GAPDH probe was not
modified. Note lack of hybridization with the
control plasmid (pBluescript).
Fig. 5. Northern blot analysis of PAI-1 mRNAs isolated from HMrSV5 cells stimulated with 5 ng/ml TGF-b1. Treatment of HMrSV5 cells for 1 to 24
hours with 5 ng/ml TGF-b1 increased PAI-1 mRNA levels in a time-dependent manner. Note that PAI-1 mRNA was detected at 3.5 kb in unstimulated cells
(Control) and that an additional 2.4 kb species appeared after a 4 to 6 hours stimulation with TGF-b1 but decreased thereafter. By densitometric analysis, a
sixfold increase in PAI-1 mRNA accumulation was observed after 4 to 6 hours of stimulation, whereas that of the GAPDH probe was not modified.
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scars [49]. In children treated by peritoneal dialysis, the role
of PAI-1 in peritoneal fibrosis is suggested by a negative
correlation between PAI-1 concentration in dialysate and
peritoneal filtration [50].
In conclusion, we have used a well-differentiated human
peritoneal mesothelial cell culture model to further inves-
tigate the role of the fibrogenetic cytokine TGF-b1 in
peritoneal healing and fibrosis occurring after various
aggressions. TGF-b1 dramatically decreases plasmin activ-
ity by increasing PAI-1 secretion, and may thus enhance
fibrin deposition and further extracellular accumulation of
interstitial collagens. Moreover, TGF-b1-induced accumu-
lation of PAI-1 in ECM may inhibit mesothelial cell
migration which is necessary for the restoration of a
continuous cell lining along the peritoneal cavity and the
synthesis of a new basement membrane. Further in vitro
studies using this relevant model are required to test the
effects of novel dialysates and drugs that could limit
peritoneal fibrosis and consequently, prevent the loss of
ultrafiltration in patients treated with peritoneal dialysis.
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Fig. 7. Immunogold silver staining (IGSS) and immunofluorescence (IF) studies of PAI-1 in control and TGF-b1-stimulated mesothelial HMrSV5
cells. Subconfluent cell cultures grown on collagen coated glass slides were stimulated (B, D) or not (A, C) with TGF-b1 (5 ng/ml) for 4 (B) and 24 hours
(D) as described in the Methods section. For IF studies, permeabilized cells were incubated with the anti-PAI-1 monoclonal antibody and were then
labeled with a biotinylated anti-mouse IgG antibody and avidin conjugated to FITC. For IGSS, the slides were incubated with the anti-PAI-1 monoclonal
antibody before treatment with gold-labeled goat anti-mouse F(ab9)2, followed by amplification with the silver enhancement reagent and by
counterstaining with Giemsa. The slides were examined with combined brightfield and epipolarization microscopy. Intracellular PAI-1 was detected by
IF as small intracytoplasmic, mostly perinuclear vesicles in control cell cultures (A, arrowheads). After four hours of exposure to TGF-b1, a dramatic
increase in intracellular PAI-1 was observed with an increased number and size of PAI-1 containing intracytoplasmic vesicles (B, arrowheads) (bar, 5
mm). Extracellular PAI-1 was localized by IGSS in the close pericellular environment of cells in control cultures (C, arrows). After 24 hours of TGF-b1
stimulation, extracellular PAI-1 increased and spread over the whole extracellular matrix surface uncovered by the cells (D, large arrows) (bar, 60 mm).
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APPENDIX
Abbreviations used in this article are: Ag, antigen; CAPD, continuous
ambulatory peritoneal dialysis; Cxd, cycloheximide; ECM, extracellular
matrix; HMrSv5, human peritoneal mesothelial immortalized cell line; IF,
immunofluorescence; IGSS, immunogold silver staining technique; MMP,
matrix metalloproteinase; PA, plasminogen activator; PAI, plasminogen
activator inhibitor; PD, peritoneal dialysis; TGF-b, transforming growth
factor-beta; tPA, tissue-type plasminogen activator; uPA, urokinase plas-
minogen activator; VNr, vitronectin receptor.
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